1207989-22-7

LGD-6972 sodium is a selective and orally active glucagon receptor antagonist. LGD-6972 sodium has the potential for type 2 diabetes research[1].

[1] Vajda EG, et al. Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2017 Jan;19(1):24-32. DOI:10.1111/dom.12752